NCT06212401View on ClinicalTrials.gov

Dexmedetomidine Versus Ketofol for Moderate Sedation in Endoscopic Retrograde Cholangiopancreatography

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Sedation
Interventions
DRUG

Dexmedetomidine

Patients received dexmedetomidine as a bolus over 10 minutes in a dose of 1ug/kg followed by an infusion at the rate of 0.5ug/kg/hr

DRUG

Ketofole

Patients received ketofol 1mg/kg over 10 minutes followed by 50ug/kg/min of infusion

Trial Locations (1)

74200

Sindh Institute of Urology and Transplantation, Karachi

All Listed Sponsors
lead

Sindh Institute of Urology and Transplantation

OTHER

NCT06212401 - Dexmedetomidine Versus Ketofol for Moderate Sedation in Endoscopic Retrograde Cholangiopancreatography | Biotech Hunter | Biotech Hunter